Fuchs beats fourth quarter estimates on solid results

Q4 sales €863.0m (+0.5% YoY) beat consensus by ~2% (consensus €848m); Q4 EBIT €109.0m was flat YoY and ahead of consensus €107.4m, yielding a 12.6% margin vs 11.6% a year earlier. FY2025 sales €3,563m (+1% YoY) and EBIT €435m (up marginally); adjusted EPS rose ~2% to €2.34 (preference) / €2.33 (ordinary). FY2026 guidance: sales around €3.7bn (guidance midpoint ~2% above analyst consensus €3.628bn) and EBIT ~€450m (1–2% below consensus €454–459m); free cash flow before acquisitions guided ~€270m (vs €307m consensus) and will be impacted by OPET integration and digitalization costs.

Analysis

Management’s willingness to absorb one-off integration and digitalization costs signals a trade-off: near-term cash conversion and margins will be noisier, but the acquisition creates a multi-year optionality for cross-selling and scale in additive-intensive markets. Expect working-capital drag and elevated capex/digital spend to depress free cash flow for the next 2-4 quarters even if underlying volumes remain resilient.

The company’s decentralized footprint and aftermarket orientation are underappreciated defensive features versus bulk chemical peers: aftermarket revenues shorten visibility but increase margin stickiness during industrial slowdowns because pricing and service contracts are less cyclical than OEM volumes. That structural resilience should translate to narrower cashflow volatility vs commodity-facing suppliers if management executes integration cleanly over 6-18 months.

Key risks are integration execution, FX and base-oil/commodity swings that can swing margins quickly, and a gradual secular hit from EV adoption that trims ICE lubricant demand over years — none are binary within 12 months but all can flip the story over 2-5 years. Watch quarterly FCF recovery, working-capital trends, and disclosure of realized synergies; they are the high-leverage catalysts that will re-rate the equity within three quarters.

Key Decisions for Investors

• Long FPEn (ETR:FPEn) equity on a >6-8% post-earnings pullback, target 18-25% upside over 6-12 months; place a 12% hard stop below entry to limit downside from integration disappointment.
• Call-spread: buy 9–12 month FPEn calls and sell nearer-dated calls to fund cost (calendar call spread). Rationale: pays if integration visibility improves by next two quarters; aim for 2.5x upside vs premium paid, max loss = premium.
• Relative-value pair: long FPEn / short Evonik (EVK.DE) equal notional for 6–9 months. Trade the resilience of aftermarket and decentralized network vs cyclic specialty chemicals exposure; target 10–15% relative outperformance, stop if spread widens >8% adverse.
• Event hedge: buy short-dated puts (30–60 days) sized to cover ~25% of position ahead of next quarterly release and FCF update; cost is insurance against near-term downside from integration surprises while keeping upside exposure.
• Monitor catalyst triggers (WC trends, synergy realization, FCF recovery). If synergies are confirmed within two quarters, rotate half position from options into stock to capture durable multiple expansion.